News Releases

Synlogic Presents Data Demonstrating Reductions in Plasma Phenylalanine Levels in Patients with Phenylketonuria Treated with SYNB1618

Synlogic Reports Third Quarter Financial Results and Provides Business Update

Synlogic Announces Presentation of Phenylketonuria Data at 14th International Congress of Inborn Errors of Metabolism Meeting

Synlogic and Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria

Synlogic Announces Third Quarter 2021 Conference Call & Participation in Upcoming Banking Conference

Synlogic Announces Nature Communications Publication Highlighting Use of Synthetic Biotic Platform to Optimize Therapies for Phenylketonuria

Synlogic Presents Data on Hyperoxaluria Program at American Society of Nephrology Kidney Week 2021

Synlogic Announces Nature Publication Demonstrating Novel Application of Synthetic Biotic Platform

Synlogic Appoints Molly Harper as Chief Business Officer

Synlogic Announces Pricing of Public Offering of Common Stock

Synlogic Announces Proposed Public Offering of Common Stock

Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria

Synlogic Therapeutics